Therefore, our study aimed to investigate for the first time the frequency of circulating CD4+ T cells with varying levels of CD26 by flow cytometry in metastatic melanoma patients treated with nivolumab compared to healthy subjects. This evidence concerns the gene CD4 and metastatic melanoma.